A phase III, multicenter, open-label study to evaluate the control of gastric acid secretion with esomeprazole in patients with gastric acid hypersecretory states including idiopathic hypersecretion and Zollinger-Ellison syndrome for 12 months

Trial Profile

A phase III, multicenter, open-label study to evaluate the control of gastric acid secretion with esomeprazole in patients with gastric acid hypersecretory states including idiopathic hypersecretion and Zollinger-Ellison syndrome for 12 months

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Hyperchlorhydria; Zollinger-Ellison syndrome
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2009 Actual end date (July 2005) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Actual initiation date (July 2003) added as reported by ClinicalTrials.gov.
    • 16 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top